Research ArticleAccepted Article
Gastrointestinal adverse drug reaction profile of etanercept: real world data from patients and healthcare professionals
Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Bart J.F. van den Bemt, Michael T. Nurmohamed, Martijn B.A. van Doorn, Phyllis I. Spuls, Astrid M. van Tubergen, Peter M. ten Klooster, Eugene P. van Puijenbroek, Frank Hoentjen and Harald E. Vonkeman
The Journal of Rheumatology May 2021, jrheum.201373; DOI: https://doi.org/10.3899/jrheum.201373
Jette A. van Lint
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Naomi T. Jessurun
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Sander W. Tas
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Bart J.F. van den Bemt
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Michael T. Nurmohamed
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Martijn B.A. van Doorn
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Phyllis I. Spuls
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Astrid M. van Tubergen
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Peter M. ten Klooster
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Eugene P. van Puijenbroek
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Frank Hoentjen
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Harald E. Vonkeman
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Abstract
Objective We aimed to describe the nature and frequency of gastrointestinal adverse drug reactions (GI-ADRs) of etanercept (ETN) using patient-reported and healthcare professional (HCP)-registered data and compared this frequency with the GI-ADR frequency of the widely used TNFα-inhibitor adalimumab.
Methods Reported GI-ADRs of ETN for rheumatic diseases were collected from the Dutch Biologic Monitor and DREAM registries. We described the clinical course of GI-ADRs and compared the frequency with adalimumab in both data sources using a Fisher’s exact test.
Results Out of 416 patients using ETN for inflammatory rheumatic diseases in the Dutch Biologic Monitor, 25 patients (6%) reported 36 GI-ADRs. In the DREAM registries 11 GI-ADRs were registered for 9 patients (2.3%), out of 399 patients using ETN, with an incidence of 7.14 per 1000 patient years. Most GI-ADRs concerned diarrhoea, nausea and abdominal pain. GI-ADRs led to ETN discontinuation in one patient (4%) and dose adjustment in four (16%) in the Dutch Biologic Monitor. Eight GI-ADRs (73%) led to ETN discontinuation in the DREAM registries. The frequency of GI-ADRs of ETN did not significantly differ from GI-ADRs of adalimumab in both data sources (Dutch Biologic Monitor: ETN 8.7% vs. ADA 5.3%, p=0.07; DREAM: ETN 2.8% vs. ADA 4.7%, p=0.16).
Conclusion Most GI-ADRs associated with ETN concerned gastrointestinal symptoms. These ADRs may lead to dose adjustment or ETN discontinuation. The frequency of ETN associated GI-ADRs was comparable to the frequency of adalimumab associated GI-ADRs. Knowledge about these previously unknown ADRs can facilitate early recognition and improve patient communication.
In this issue
The Journal of Rheumatology
Vol. 49, Issue 9
1 Sep 2022
Accepted manuscript
Gastrointestinal adverse drug reaction profile of etanercept: real world data from patients and healthcare professionals
Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Bart J.F. van den Bemt, Michael T. Nurmohamed, Martijn B.A. van Doorn, Phyllis I. Spuls, Astrid M. van Tubergen, Peter M. ten Klooster, Eugene P. van Puijenbroek, Frank Hoentjen, Harald E. Vonkeman
The Journal of Rheumatology May 2021, jrheum.201373; DOI: 10.3899/jrheum.201373
Accepted manuscript
Gastrointestinal adverse drug reaction profile of etanercept: real world data from patients and healthcare professionals
Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Bart J.F. van den Bemt, Michael T. Nurmohamed, Martijn B.A. van Doorn, Phyllis I. Spuls, Astrid M. van Tubergen, Peter M. ten Klooster, Eugene P. van Puijenbroek, Frank Hoentjen, Harald E. Vonkeman
The Journal of Rheumatology May 2021, jrheum.201373; DOI: 10.3899/jrheum.201373
